Facebook Pixel Innovation – The next frontier | Express Pharma - Health - Lee esta historia en Magzter.com

Intentar ORO - Gratis

Innovation – The next frontier

Express Pharma

|

October 2020

Alok Ghosh, Ex-President - Global Technical Operations, Lupin, underscores the importance of creating a conducive environment to foster innovation in India’s life sciences sector to ensure its continuous progress

- Alok Ghosh

Innovation – The next frontier

The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.

Essentially two developments have happened in the last couple of years:

1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.

2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.

MÁS HISTORIAS DE Express Pharma

Express Pharma

Express Pharma

Glass vs other pharma packaging materials: Safeguarding purity, enhancing trust

Rajesh Khosla, CEO, AGI Greenpac explains why glass stands out as a trusted material that continues to meet modern pharma's safety and sustainability demands

time to read

3 mins

March 2026

Express Pharma

Express Pharma

WHEN She LEADS

Women shaping pharma today share honest lessons and real-world leadership wisdom for the next generation of women who dare to lead

time to read

15 mins

March 2026

Express Pharma

Express Pharma

Our approach is to combine localised production with global quality standards

Jean Charles Wirth, Global CEO of Merck Life Science, shares insights on the company's approach in a price conscious and quality focused market like India, the company's close alignment with the 'Make in India' vision and how Merck is fostering scientific talent to support customers in India, the Asia-Pacific region, and globally, in an interaction with Viveka Roychowdhury

time to read

3 mins

March 2026

Express Pharma

Express Pharma

India has the infrastructure to lead the global gene therapy market

Professor Philip J. Young, Director of Educational Analytics, School of Life Sciences, University of Warwick, outlines how AI is compressing drug discovery timelines, why affordability remains the real bottleneck in SMA care, and how India can lead the next phase of precision medicine, in an exclusive interview with Neha Aathavale

time to read

8 mins

March 2026

Express Pharma

Express Pharma

Industrial and infrastructure sectors are undergoing rapid modernisation

In the pharma sector, precision is non-negotiable and compliance is constant. Attention often focuses on formulations and manufacturing processes; yet the foundation of operational excellence lies in infrastructure - the systems that quietly ensure safety, efficiency and regulatory adherence. Jinali Gandhi, Director at Gandhi Automations, represents a new generation of leaders shaping this critical dimension of the industry

time to read

2 mins

March 2026

Express Pharma

Express Pharma

Targeted incentives for innovation-driven research would further strengthen India's biotech ecosystem

Venkat Nelabhotla, Co-Founder, President and CEO of Vyome Holdings, shares how focused innovation, disciplined development and policy support can accelerate India's emergence as a global biotech innovation hub, in an interview with Lakshmipriya Nair

time to read

3 mins

March 2026

Express Pharma

Express Pharma

Partners in Progress: PPL 2026

PPL 2026 brought together India's pharma packaging ecosystem to explore how collaboration, innovation, and technical expertise can strengthen patient safety, product stability, and operational efficiency. Across partner-led sessions, speakers discussed how structured systems, material science, regulatory alignment, and technology integration collectively elevate packaging from a support function to a strategic enabler.

time to read

2 mins

March 2026

Express Pharma

Express Pharma

What truly differentiates Transchem is our technical-first approach

Sanjay Lanke, VP - Technical Business Development, Transchem Corporation Pharma, outlines its focus on innovation, strategic partnerships, and portfolio diversification to support complex formulations while expanding its presence across pharma, nutraceutical, and food ingredient markets, in an interview with Lakshmipriya Nair

time to read

3 mins

March 2026

Express Pharma

Express Pharma

Tech, trust and traceability: Shaping India pharma's future

At the PPL Conclave 2026, hosted by Express Pharma, industry leaders explored how innovation, operational excellence and evolving regulations are positioning packaging as a strategic driver in India's pharma growth, reports Neha Aathavale

time to read

7 mins

March 2026

Express Pharma

Express Pharma

In 2026, India serves as the reliable 'technical engine' for global research

Dr Seema Pai, President, Indian Society for Clinical Research outlines how India's clinical research landscape is evolving into a quality-driven, innovation-led ecosystem, supported by regulatory progress, digital adoption, and stronger patient-centric approaches positioning the country as a global research hub, in an interview with Swati Rana

time to read

6 mins

March 2026

Translate

Share

-
+

Change font size